Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Receivables (2019 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Receivables for 7 consecutive years, with $126.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 93.17% year-over-year to $126.5 million, compared with a TTM value of $126.5 million through Dec 2025, up 93.17%, and an annual FY2025 reading of $126.5 million, up 93.17% over the prior year.
  • Receivables was $126.5 million for Q4 2025 at Catalyst Pharmaceuticals, up from $106.4 million in the prior quarter.
  • Across five years, Receivables topped out at $126.5 million in Q4 2025 and bottomed at $5.6 million in Q1 2021.
  • Average Receivables over 5 years is $42.7 million, with a median of $45.4 million recorded in 2023.
  • The sharpest move saw Receivables decreased 19.04% in 2021, then skyrocketed 414.61% in 2023.
  • Year by year, Receivables stood at $6.6 million in 2021, then skyrocketed by 57.71% to $10.4 million in 2022, then skyrocketed by 412.64% to $53.5 million in 2023, then rose by 22.35% to $65.5 million in 2024, then surged by 93.17% to $126.5 million in 2025.
  • Business Quant data shows Receivables for CPRX at $126.5 million in Q4 2025, $106.4 million in Q3 2025, and $65.9 million in Q2 2025.